ALLO

TentativeAI Memo

Allogene Therapeutics

As of 2026-10-14/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-14 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report

Action

—

Confidence

medium

Horizon

—

Key catalyst

ALPHA3 site activation and enrollment execution • 2026-12-31

Base target: $1 / p=35% prob

Biggest risk

The ALPHA3 MRD comparison is based on only 24 patients and is not an event-free-survival result. Weak ALLO-329 efficacy, safety or lymphodepletion data, slower enrollment, or further dilution could outweigh the reported runway. The deterministic prior remains negative.

Invalidation

Break below $1 or thesis failure.

What would change my mind?

A credible ALLO-329 signal and eventual confirmation that ALPHA3 MRD clearance improves event-free survival could substantially improve the platform thesis. Allogene reported $423.6 million of cash, cash equivalents and investments at June 30, 2026 and projected runway into 2029 [#SEC-8K-2026-08-12].

Research note

Recommendation

—

Confidence

medium

As of

2026-10-14

Base target

p=35%

Bull target

p=20%

Bear target

p=45%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q4 2026 ALLO-329 clinical update
Mid-2027 ALPHA3 interim event-free-survival analysis
A credible ALLO-329 signal and eventual confirmation that ALPHA3 MRD clearance improves event-free survival could substantially improve the platform thesis.

BearKey bullets

ALLO-329 remains in Phase 1, with unresolved efficacy, safety and lymphodepletion questions across autoimmune indications.
Early ALPHA3 MRD clearance may not translate into durable event-free-survival benefit; interim data may not predict final results.
The September 2 SEC filing reported CFO Geoffrey Parker's retirement effective November 6, 2026, adding a near-term management-transition item [#8-K-2026-09-02].

WatchKey bullets

ALPHA3 site activation and enrollment execution

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $1 (p=35%)

Target spread vs base: +92% / -56%

Scenario probabilities

Bull Target: $2 (p=20%)Base Target: $1 (p=35%)Bear Target: $1 (p=45%)

Commentary

The October 13 anchor of $1.29 is below the prior baseline's September 21 anchor of $1.69, consistent with continued caution, although those two points do not establish the cause of the decline. Stored Zacks coverage reported an approximately 11.1% share loss in the month after Q2 results and said estimates had moved upward; no dependable current analyst target-change set was supplied. Social, options, short-interest and employee measures were unavailable; zeros above are placeholders, not observed neutral readings. The Q2 company release and its SEC-filed exhibit support the clinical timetable and financial figures [#SEC-8K-2026-08-12].

As of 2026-10-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Q4 2026 ALLO-329 clinical update
Mid-2027 ALPHA3 interim event-free-survival analysis

Scenarios

Bull Target (Scenario probability)

$2 / p=20% prob

Base Target (Scenario probability)

$1 / p=35% prob

Bear Target (Scenario probability)

$1 / p=45% prob

Analysis 2026-10-14 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-12-31
ALPHA3 site activation and enrollment execution
After activating more than 80 ALPHA3 sites, Allogene expects approximately 100 active sites by year-end 2026. Reaching that goal could support enrollment confidence, but site count alone would not establish clinical benefit [#SEC-8K-2026-08-12].
Prob 75.00% • Move 8.00% • Priced-in 70.00%

Short-term Catalysts

Next few weeks

Q4 2026 ALLO-329 clinical update
2026-12-31
Allogene expects clinical and translational data from the Phase 1 RESOLUTION autoimmune-disease trial in Q4 2026. Activity, safety and results from cohorts testing reduced or no conventional lymphodepletion are the key questions. The timing is a company expectation, not a confirmed readout date [#SEC-8K-2026-08-12].
Prob 75% • Move 25% • Priced-in 35%

Long-term Catalysts

Months to a year

Mid-2027 ALPHA3 interim event-free-survival analysis
2027-06-30
The initial 24-patient assessment found MRD negativity in 7 of 12 cema-cel patients versus 2 of 12 under observation. Allogene expects the next program update, tied to an interim event-free-survival analysis, in mid-2027. Whether early MRD clearance translates into durable clinical benefit remains unproven [#SEC-8K-2026-08-12].
Prob 55% • Move 50% • Priced-in 25%

Risks

ALLO-329 remains in Phase 1, with unresolved efficacy, safety and lymphodepletion questions across autoimmune indications.
Early ALPHA3 MRD clearance may not translate into durable event-free-survival benefit; interim data may not predict final results.
The September 2 SEC filing reported CFO Geoffrey Parker's retirement effective November 6, 2026, adding a near-term management-transition item [#8-K-2026-09-02].
Trial enrollment, manufacturing, regulatory decisions and capital needs could change the projected cash runway.

Peers

Symbol	Summary
RCKT	A clinical-stage biotech comparison identified in stored earnings coverage. Different therapeutic programs and modalities make it useful mainly for assessing milestone and financing sensitivity, not for a direct price multiple.
CLLS	A relevant allogeneic cell-therapy development comparator, though its distinct pipeline and milestone timing limit valuation read-through. Allogene's Q2 company release identifies Cellectis technology in its investigational oncology products; this does not make the two stocks interchangeable valuation peers.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-14

Loading AI feed…

Symbol

Summary

RCKT

A clinical-stage biotech comparison identified in stored earnings coverage. Different therapeutic programs and modalities make it useful mainly for assessing milestone and financing sensitivity, not for a direct price multiple.

CLLS

A relevant allogeneic cell-therapy development comparator, though its distinct pipeline and milestone timing limit valuation read-through. Allogene's Q2 company release identifies Cellectis technology in its investigational oncology products; this does not make the two stocks interchangeable valuation peers.